Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pRNA-HER2apt-siMED1
- Development stage
- Preclinical
- Lead developer
- University of Cincinnati
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
pRNA-HER2apt-siMED1 is a preclinical RNA nanotechnology-based therapeutic candidate developed by the University of Cincinnati and its spinout startup, RNA Nanotherapeutics. It is designed to treat HER2-overexpressing, estrogen receptor-positive (ER+) breast cancers, particularly those that have developed resistance to endocrine therapies like tamoxifen. The therapeutic consists of a three-way junction (3-WJ) packaging RNA (pRNA) nanoparticle harboring a HER2-targeting RNA aptamer for tumor-specific delivery and two small interfering RNAs (siRNAs) targeting Mediator Subunit 1 (MED1). By silencing MED1, a key ER transcriptional coactivator that co-amplifies with HER2 and drives therapeutic resistance, the nanoparticle depletes MED1 expression, attenuates ERα-mediated gene transcription, and suppresses tumor growth, metastasis, and cancer stem cell formation.
- Other names
- pRNA-HER2apt-siMED1 RNA nanoparticlespRNA-HER-2apt-siMED1 RNA nanoparticlespRNA-HER 2apt-siMED1 RNA nanoparticlespRNA-HER2apt-siMED1 nanoparticlespRNA-HER-2apt-siMED1 nanoparticlespRNA-HER 2apt-siMED1 nanoparticles
02
Targets
MED1 (Mediator of RNA polymerase II transcription subunit 1)ESR1 (ERα)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on pRNA-HER2apt-siMED1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pRNA-HER2apt-siMED1.